Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of surgical-site infection in primary hip and knee arthroplasty with mupirocin and chlorhexidine
NL-OMON41616Not yet recruiting
- Sponsor
- Isala
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of mupirocin and chlorhexidine in surgical site infection (SSI) and Staphylococcus aureus infection (2 arms), sponsored by Isala. Primary endpoint: Reduction in surgical site infection. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
mupirocinchlorhexidine
03
Conditions
surgical site infection (SSI)Staphylococcus aureus infection
Beyond the preview
Go deeper on NL-OMON41616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41616.